1. Clinical & Scientific Overview
Chlordiazepoxide IP (TIP-MED-000406, Reference Code [11.15]-CMP136) is classified under
Neurology & Antiepileptic Medicines (Ch 11) as a Long-Acting Lipophilic Benzodiazepine (Anticonvulsant, Anxiolytic, Skeletal Muscle Relaxant).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).
Co-indexed per approved Author Decision DEC-06 (Option 6A; displaced HTML [11.18]). Long-acting benzodiazepine (Librium 10/25 mg) for CIWA-Ar acute alcohol withdrawal.
Standard approved strengths (refer to comparative context)
3. Mechanism of Action & Pharmacodynamics
Co-indexed per approved Author Decision DEC-06 (Option 6A; displaced HTML [11.18]). Long-acting benzodiazepine (Librium 10/25 mg) for CIWA-Ar acute alcohol withdrawal.
4. Therapeutic Indications & Evidence-Supported Uses
- Status epilepticus and febrile convulsions (IV or rectal)
- acute alcohol withdrawal syndrome
- severe acute muscle spasm
- tetanus spasms
- acute procedural anxiety
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-06 (Option 6A; displaced HTML [11.18]). Long-acting benzodiazepine (Librium 10/25 mg) for CIWA-Ar acute alcohol withdrawal.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Comparative pharmacokinetic profile co-indexed under [11.15].
Renal: eGFR <30 mL/min: Active glucuronide and desmethyldiazepam metabolites accumulate; reduce dose and avoid repeated boluses. • Hepatic: Mild-moderate cirrhosis: Half-life doubles to quadruples; reduce dose by 50% (prefer Lorazepam). Severe hepatic failure: Contraindicated.
Renal: eGFR <30 mL/min: Active glucuronide and desmethyldiazepam metabolites accumulate; reduce dose and avoid repeated boluses. • Hepatic: Mild-moderate cirrhosis: Half-life doubles to quadruples; reduce dose by 50% (prefer Lorazepam). Severe hepatic failure: Contraindicated.
Renal: eGFR <30 mL/min: Active glucuronide and desmethyldiazepam metabolites accumulate; reduce dose and avoid repeated boluses. • Hepatic: Mild-moderate cirrhosis: Half-life doubles to quadruples; reduce dose by 50% (prefer Lorazepam). Severe hepatic failure: Contraindicated.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Severe respiratory insufficiency, myasthenia gravis, severe hepatic failure, untreated sleep apnoea, neonatal hyperbilirubinaemia (injectable benzyl alcohol/benzoate vehicle). • Precautions: High risk of accumulation and prolonged coma in elderly and cirrhotic patients; do not give IM (erratic painful absorption) or dilute in standard PVC infusion bags (adsorbs to plastic).
Key Clinical Precautions: Renal: eGFR <30 mL/min: Active glucuronide and desmethyldiazepam metabolites accumulate; reduce dose and avoid repeated boluses. • Hepatic: Mild-moderate cirrhosis: Half-life doubles to quadruples; reduce dose by 50% (prefer Lorazepam). Severe hepatic failure: Contraindicated.
8. Adverse Effects Profile
- Drowsiness, fatigue, ataxia, hangover sedation.
- Apnoea/hypotension (rapid IV), venous thrombophlebitis, severe withdrawal syndrome.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Omeprazole / Fluconazole / Fluvoxamine (CYP2C19/3A4 inhibitors) -> markedly prolong diazepam sedation; Opioids / Alcohol -> fatal CNS/respiratory depression
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [11.15].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Sedative effects persist into the next day due to long-acting breakdown products; avoid driving and alcohol; taper gradually under medical supervision.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablet: 2 mg, 5 mg, 10 mg; Injection: 5 mg/mL (2 mL ampoule = 10 mg); Rectal Solution/Suppository: 5 mg, 10 mg.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.15] Diazepam (Oral, IV & Paediatric Rectal Protocol) — Long-Acting Lipophilic Benzodiazepine (Anticonvulsant, Anxiolytic
- [11.16] Midazolam (Parenteral & Intranasal Rescue Protocol) — Short-Acting Water-Soluble Imidazobenzodiazepine (Intranasal / Bu
- [11.27] Levodopa + Carbidopa (Co-Careldopa) & Pramipexole — Dopamine Precursor + Peripheral DOPA Decarboxylase Inhibitor & No
- [11.28] Lamotrigine & Topiramate — Broad-Spectrum Antiepileptics, Bipolar Mood Stabiliser & Migraine